Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
We also offer in-office injections for those who live in the area, free of charge
Mounjaro provides metabolic, cardiovascular, and blood glucose benefits beyond weight loss alone
Key Research Findings Clinical Research : Has identified specific risk patterns among different patient populations: Diabetic patients using GLP-1 drugs showed a 4.28-fold increased risk of developing NAION compared to those on alternative diabetes medications Overweight or obese patients prescribed these agents demonstrated a 7.64-fold elevated risk relative to individuals using other weight management therapies The cumulative incidence rate suggested approximately 8.9 cases per 10,000 patient-years among GLP-1 receptor agonist users Additional Studies: Documented in medical literature have examined various eye manifestations beyond NAION
This means that the primary way metformin helps regulate glucose levels is perhaps by directly affecting how glucose is processed in the intestines
Meet our doctors Last reviewed: 19 Jun 2026 Sources Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients (2020) NIH [accessed 27 January 2026] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial (2023) The Lancet [accessed 27 January 2026] How to use Mounjaro (2023) Mounjaro [accessed 27 January 2026] Lillys SURMONT-2 results published in The Lancet show tirzepatide achieve a mean weight reduction of 15.7% at the highest dose (15mg) in adults with obesity or overweight and type 2 diabetes (2023) Lillys INVESTORS [accessed 27 January 2026] MHRA authorised diabetes drug Mounjaro (tirzepatide) for weight management and weight loss (2023) GOV.UK
DOI: 10.1016/j.bcp.2018.05.003
